Frazier Life Sciences | Activity | F4Frazier Life Sciences Activity
Every public signal F4 has attached to this firm, with sources and cross-entity links.
News
Portfolio company Braveheart Bio priced an upsized $382.5M IPO on Nasdaq (BRVE).
Braveheart Bio IPO
Portfolio company Attovia Therapeutics priced an upsized $289M IPO on Nasdaq (ATTO).
Investment
Led Crystalys Therapeutics' oversubscribed $130M Series B to advance Phase 3 development of dotinurad for gout.
Crystalys Therapeutics
Exit
Portfolio company KalVista Pharmaceuticals agreed to be acquired by Chiesi Group for approximately $1.9B (completed June 2026).
KalVista Pharmaceuticals
Exit
Portfolio company Tubulis agreed to be acquired by Gilead Sciences for up to $5B (completed May 2026).
Tubulis
Investment
Led AirNexis Therapeutics' $200M Series A launch to advance a Phase 2 dual PDE3/4 inhibitor for COPD.
AirNexis Therapeutics
Investment
Joined as a new investor in Parabilis Medicines' oversubscribed $305M Series F financing.
Parabilis Medicines
New Fund
Closed FLS XII, an oversubscribed $1.3B venture fund, its largest venture fund to date.
Frazier Life Sciences XII (FLS XII)
New Fund
Added over $630M to its evergreen Public Fund, bringing total public fund capital raised since 2021 to ~$1.7B.
Evergreen Public Fund capital raise